The European Commission has granted marketing approval to darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC). The move comes after the 2020 approval of the drug, marketed under the brand name Nubeqa for its first indication: non-metastatic castration-resistant prostate cancer.

Darolutamide reduces the risk of death from mHSPC by 32.5% compared ...